These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21621856)

  • 1. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier.
    Hosokawa T; Nakajima H; Doi Y; Sugino M; Kimura F; Hanafusa T; Takahashi T
    J Neuroimmunol; 2011 Jul; 236(1-2):81-6. PubMed ID: 21621856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.
    Uchida T; Mori M; Uzawa A; Masuda H; Muto M; Ohtani R; Kuwabara S
    Mult Scler; 2017 Jul; 23(8):1072-1084. PubMed ID: 27682231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis.
    Liuzzi GM; Trojano M; Fanelli M; Avolio C; Fasano A; Livrea P; Riccio P
    Mult Scler; 2002 May; 8(3):222-8. PubMed ID: 12120694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica.
    Zhong X; Wang H; Dai Y; Wu A; Bao J; Xu W; Cheng C; Lu Z; Qiu W; Hu X
    J Neuroimmunol; 2011 Dec; 240-241():104-8. PubMed ID: 22036953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-4 in cerebrospinal fluid with blood-brain barrier dysfunction in patients with eosinophilic meningitis caused by Angiostrongylus cantonensis.
    Tsai HC; Chung LY; Chen ER; Liu YC; Lee SS; Chen YS; Sy CL; Wann SR; Yen CM
    Am J Trop Med Hyg; 2008 Jan; 78(1):20-7. PubMed ID: 18187780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
    Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y
    Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica.
    Jiang Y; Yang Y; Zhang B; Peng F; Bao J; Hu X
    Neuro Endocrinol Lett; 2009 Mar; 30(1):85-90. PubMed ID: 19300400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability.
    Tomizawa Y; Yokoyama K; Saiki S; Takahashi T; Matsuoka J; Hattori N
    J Int Med Res; 2012; 40(4):1483-91. PubMed ID: 22971500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica.
    Wang H; Wang K; Zhong X; Dai Y; Qiu W; Wu A; Hu X
    Neuroimmunomodulation; 2012; 19(5):304-8. PubMed ID: 22777162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.
    Kim WU; Min SY; Cho ML; Hong KH; Shin YJ; Park SH; Cho CS
    Arthritis Res Ther; 2005; 7(1):R71-9. PubMed ID: 15642145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High CSF neurofilament heavy chain levels in neuromyelitis optica.
    Miyazawa I; Nakashima I; Petzold A; Fujihara K; Sato S; Itoyama Y
    Neurology; 2007 Mar; 68(11):865-7. PubMed ID: 17353477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica.
    Uzawa A; Mori M; Masuda S; Kuwabara S
    Arch Neurol; 2011 Jul; 68(7):913-7. PubMed ID: 21747031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis.
    Chang KH; Tseng MY; Ro LS; Lyu RK; Tai YH; Chang HS; Wu YR; Huang CC; Hsu WC; Kuo HC; Chu CC; Chen CM
    Clin Chim Acta; 2013 Feb; 417():26-30. PubMed ID: 23262373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
    Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of serum gamma-glutamyltransferase and C-reactive proteins with neuromyelitis optica and multiple sclerosis.
    Shu Y; Li R; Qiu W; Chang Y; Sun X; Fang L; Chen C; Yang Y; Lu Z; Hu X; Kermode AG
    Mult Scler Relat Disord; 2017 Nov; 18():65-70. PubMed ID: 29107207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica.
    Liu C; Xu Y; Cui L; Wang J; Peng B; Zhong L; Chen X
    J Clin Neurosci; 2013 Feb; 20(2):278-80. PubMed ID: 23164828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease.
    Fujimura M; Watanabe M; Narisawa A; Shimizu H; Tominaga T
    Surg Neurol; 2009 Nov; 72(5):476-80; discussion 480. PubMed ID: 19147196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.